The GPI anchor pathway: a promising antifungal target?

  title={The GPI anchor pathway: a promising antifungal target?},
  author={Mitchell W. Mutz and Terry Roemer},
  journal={Future medicinal chemistry},
  volume={8 12},
A key challenge with developing antifungal drugs is that both humans and fungi are eukaryotic organisms; as a result, antifungal therapeutics may have substantial toxicity due to inhibition of closely related human targets. Compounding this challenge, the principal clinically relevant fungal pathogens Aspergillus fumigatus and Candida albicans diverged from a common ancestor 1 billion years ago [1], underscoring their substantial genetic and pathogenic diversity and the difficulty of new… 

Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens

The increased risk of invasive fungal infections associated with use of calcineurin inhibitors as immunosuppressants may be mitigated by their synergistic fungicidal interaction with (fos)manogepix and its ability to enhance exposure of immunostimulatory glucans.

Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.

A comprehensive review of the progress made to date in the development of fungal cell wall inhibitors is provided, focusing on the targets, discovery process, chemical structures, antifungal activities and structure-activity relationships.

Fungal Cell Wall: Emerging Antifungals and Drug Resistance

This review summarizes recent findings regarding antifungal therapy and development of resistance related to the fungal cell wall of the most relevant human pathogenic species.

Antifungal Activity of Gepinacin Scaffold Glycosylphosphatidylinositol Anchor Biosynthesis Inhibitors with Improved Metabolic Stability

Gepinacin demonstrates broad-spectrum antifungal activity and negligible mammalian toxicity in culture but is metabolically labile, and structure-activity relationships identified here suggest strategies to further improve compound potency, solubility, and stability.

Role of Protein Glycosylation in Interactions of Medically Relevant Fungi with the Host

This review focuses on describing the relationship between protein glycosylation and the host–immune interaction in medically relevant fungal species.

Generating anchors only to lose them: The unusual story of glycosylphosphatidylinositol anchor biosynthesis and remodeling in yeast and fungi

The present Review focuses on the biosynthetic pathway in Saccharomyces cerevisiae, which has for long been studied as a model organism and appears that several phenotypes are unique to a specific step in the pathway and may even be species‐specific.

Deciphering Molecular Determinants Underlying Penicillium digitatum’s Response to Biological and Chemical Antifungal Agents by Tandem Mass Tag (TMT)-Based High-Resolution LC-MS/MS

Deciphering the inhibitory mechanisms of biofungicides and chemical compounds, together with understanding their effects on the fungal physiology, will provide a new direction for improving the efficacy of novel antifungal formulations and developing new control strategies.



Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.

Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis

The results establish Mcd4 as a promising antifungal target and confirm the GPI cell wall anchor synthesis pathway as aPromising antif fungus target area by demonstrating that effects of inhibiting it are more general than previously recognized.

In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections

In vivo, SM21 prevented the death of mice in a systemic candidiasis model and was also more effective than the common antifungal nystatin at reducing the extent of tongue lesions in a mouse model of oral candidiasis.

Genomic identification of potential targets unique to Candida albicans for the discovery of antifungal agents.

A comparative genomics approach was used to find out potential target proteins unique to C. albicans, an opportunistic fungus responsible for severe infection in immune-compromised human, and found many target proteins of existing antifungal agents showed orthologs in human cells.

High-Throughput Screening of a Collection of Known Pharmacologically Active Small Compounds for Identification of Candida albicans Biofilm Inhibitors

A small molecule library consisting of 1,200 off-patent drugs already approved by the Food and Drug Administration, the Prestwick Chemical Library, is screened, identifying 38 pharmacologically active agents that inhibit C. albicans biofilm formation.

Antifungal Drug Discovery: Something Old and Something New

It is sobering to consider that the gold standard therapy for cryptococcal meningitis is based on medications that were discovered nearly 50 years ago, and it took 30 years for the newest class of antifungal drugs, the echinocandins, to progress from bench-to-beside.

Antifungal drug discovery: the process and outcomes.

The dogma on antifungal discovery is examined and it is suggested that a major thrust in technologies such as structural biology, homology modeling and virtual imaging is needed to drive discovery.

Antifungal agents: mechanisms of action.